This study is assessing the combination of well known cytotoxics with a novel anti-cancer
agent that could be administered as monotherapy without renal toxicity in patients with renal
impairment presenting with advanced or metastatic urothelial carcinoma previously treated
with a platinum-based regimen. The intent of this study is to clarify the benefit/risk ratio
of the two most promising associations of cytotoxics including the novel therapeutic agent,
vinflunine: vinflunine-gemcitabine and vinflunine-carboplatin.